Mar 16, 2026 (MarketLine via COMTEX) --
Piramal said the milestone reflects the facility's advanced capabilities, operational efficiency, and technical expertise.
Piramal Pharma Solutions, a global leader in contract development and manufacturing (CDMO) and part of Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635), is proud to announce the completion of the 1,500th batch of the antibody-drug conjugate (ADC) at its dedicated bioconjugate development and manufacturing facility in Grangemouth, UK. With the 1,500th batch, a commercial oncology ADC batch, this milestone underscores the company's groundbreaking capabilities and its unwavering commitment to patient-centricity.
For over two decades, Piramal Pharma Solutions has been a global leader in the development and manufacturing of ADCs. As the first FDA-approved CDMO for ADCs and the first CDMO to commercially manufacture an ADC, Piramal demonstrates a unique competence in this segment.
Piramal leverages this expertise to offer a comprehensive range of integrated ADC solutions from Grangemouth, ranging from proof-of-concept studies to clinical and commercial scale manufacturing. These capabilities make the site a critical component of the ADCelerate™ program, Piramal's rapid, integrated Phase I ADC program. With a seamless technology transfer supported by strong program management, engineering, and quality teams, the program combines the specialized capabilities of Grangemouth with those of Piramal's global network to streamline the path from research and development to GMP production.
Building on Piramal's history as a leading ADC producer, Grangemouth has developed hundreds of unique bioconjugates and has now successfully manufactured 1,500 ADC batches, including clinical, commercial, and non-GMP batches. But the facility is not only supported by its legacy but also by the professionals of the Science Collective, who drive projects to success with their technical knowledge and strategic focus.
In line with Piramal's commitment to quality, Grangemouth maintains a strong track record in regulatory approvals and authorizations, including accreditation by the US FDA and the MHRA. With its unparalleled expertise and advanced solutions, Piramal enables the rapid, precise, and high-quality delivery of life-saving bioconjugate therapies to patients in need.
http://www.datamonitor.com
Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall
not be liable for errors or delays in the content, or for any actions
taken in reliance thereon
COMTEX_478962128/2227/2026-05-11T22:21:32
Copyright (C) 2026 Datamonitor. All rights reserved
